Ambrx (AMAM) Raises $78 Million and Completes its ATM Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Ambrx Raises $78 Million and Completes its ATM Program
March 13, 2023 8:00 AM EDTSAN DIEGO--(BUSINESS WIRE)-- Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares (ADSs) pursuant to the Companys at-the-market (ATM) program established on Aug 5, 2022, through Cowen and Company LLC (TD Cowen), acting as sales agent. The ATM program had an aggregate offering price of up to $80 million in gross proceeds. Through the utilization of the ATM, the Company has raised $78 million in net proceeds, after deducting sales commissions, thereby exhausting the capacity of the ATM and completing it.
Pursuant to... More
